论文部分内容阅读
目的:研究奈达铂联合长春瑞滨结合同步放射治疗晚期鼻咽癌的有效性和安全性。方法:选择我院收治41例病理证实为晚期鼻咽癌患者,给予奈达铂(100mg/m2,d1)和长春瑞滨(25mg/m2,d1,8)化疗,每21天为一周期,完成第一周期后行放疗,放疗期间同步化疗。结果:本组患者CR为70.7%,PR为26.8%,SD为2.4%,总有效率为97.6%,1a无复发生存率为97.6%,1a无远处转移生存率为87.8%,毒副反应主要为血液性毒性,治疗后均恢复,均可以耐受。结论:奈达铂联合长春瑞滨结合同步放射治疗晚期鼻咽癌近期疗效较好,耐受性良好且安全性较高。
OBJECTIVE: To study the efficacy and safety of nedaplatin plus vinorelbine combined with concurrent radiotherapy for advanced nasopharyngeal carcinoma. Methods: Forty-one patients with advanced nasopharyngeal carcinoma were enrolled in this study. The patients were given nedaplatin (100 mg / m2, d1) and vinorelbine (25 mg / m2, d1,8) After the completion of the first cycle of radiotherapy, concurrent chemotherapy during radiotherapy. Results: The CR was 70.7%, the PR was 26.8%, the SD was 2.4%, the total effective rate was 97.6%, the relapse-free survival rate was 97.6% and the distant metastasis-free survival rate was 87.8% Mainly for the blood toxicity, are recovered after treatment, can be tolerated. Conclusion: Nedaplatin combined with vinorelbine combined with concurrent radiotherapy for advanced nasopharyngeal carcinoma has good curative effect, good tolerability and high safety.